The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

The Incidence of Venous Thromboembolism in Family Members of Patients with Factor V Leiden Mutation and Venous Thrombosis

Saskia Middeldorp, MD; Cecilia M.A. Henkens, MD; Maria M.W. Koopman, MD; Elisabeth C.M. van Pampus, MD; Karly Hamulyak, MD; Jan van der Meer, MD; Martin H. Prins, MD; and Harry R. Buller, MD
[+] Article, Author, and Disclosure Information

From the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; University Hospital Groningen, Groningen, the Netherlands; and University Hospital Maastricht, Maastricht, the Netherlands. Acknowledgment: The authors thank Professor Jan Wouter ten Cate for his helpful comments. Grant Support: By grant 28-2783 from the Praeventiefonds. Dr. Buller is an Established Investigator of the Netherlands Heart Association. Requests for Reprints: Saskia Middeldrop, MD, Center for Haemostasis, Thrombosis, Atherosclerosis and Inflammation Research, F-4, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands. Current Author Addresses: Drs. Middeldorp, Koopman, and Buller: Center for Haemostasis, Thrombosis, Atherosclerosis and Inflammation Research, F-4, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.

Copyright ©2004 by the American College of Physicians

Ann Intern Med. 1998;128(1):15-20. doi:10.7326/0003-4819-128-1-199801010-00003
Text Size: A A A

Background: The factor V Leiden mutation is a genetic defect associated with an increased incidence of venous thromboembolism. When the incidence of venous thromboembolism in relatives of patients known to have the mutation outweighs the disadvantages of prophylactic strategies, family screening may be necessary.

Objective: To determine the incidence of venous thromboembolism in first-degree relatives of symptomatic carriers of the factor V Leiden mutation.

Design: Retrospective blinded study.

Setting: University hospitals.

Participants: 437 first-degree relatives of 112 heterozygous propositi and 30 relatives of 6 homozygous propositi.

Measurements: Before DNA testing, information on previous venous thromboembolism and concomitant risk factors was obtained. Relatives with and without the FV: Q506 mutation were compared.

Results: The annual incidence of thromboembolism in relatives of heterozygous propositi was 0.45% (95% CI, 0.28% to 0.61%) in those with the mutation and 0.10% (CI, 0.02% to 0.19%) in those without the mutation (relative risk, 4.2 [CI, 1.8 to 9.9]). Among carriers, the incidence increased from 0.25% (CI, 0.12% to 0.49%) in the 15- to 30-year-old age group to 1.1% (CI, 0.24% to 3.33%) in persons older than 60 years of age. Half of the episodes of venous thromboembolism occurred spontaneously, 20% were related to surgery, and 30% were associated with pregnancy or use of oral contraceptives.

Conclusions: The observed low annual risk for venous thromboembolism in persons carrying the factor V Leiden mutation does not seem to outweigh the risks for bleeding associated with coumarin prophylaxis or justify discouragement of the use of oral contraceptives. A general policy of screening the families of all patients with the factor V Leiden mutation does not seem to be indicated. The observations in this moderate-size, retrospective study need to be confirmed by prospective follow-up studies.


Grahic Jump Location
Figure 1.
Thromboembolic event-free survival in 437 first-degree relatives of 112 heterozygous propositi with the factor V Leiden mutation.

The black lines represent relatives without the mutation; the dashed lines represent relatives with the mutation.

Grahic Jump Location




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.